| BackgroundCoronary disease is one of the commonly mortality diseases. Atherosclerosis is characterized by a complex multifactorial pathophysiology. The mechanisms behind this phenomena have been unknown. Acute coronary syndrome (ACS) was the most emergency and servity, which also caused by the rupture of thrombosis, leading to unstable angina pectoris (UAP), acute myocardial infarction (AMI) and a sudden death. The unstable plaque play a important role in the progress of ACS. Vascular inflammation plays a major role in the initiation, progression and the final steps of atherosclerosis, namely, plaque destabilization and eventually plaque rupture. Chemokine is becoming the hot point for inducing inflammatory reaction.Chemokine is a small secreted protein molecular, which plays a important role in the inflammatory reaction by recruited T Lymphocytes and Monocytes into decidua。CXCL16 is an indicited transmembrane molecule combining scavenger receptor functions with the properties of an inflammatory chemokine. As a transmembrane molecule, CXCL16 can act as a scavenger receptor by uptaking ox-LDL to form foam cell from macrophages, promoting the development of atherosclerosis. However, the role of the circulating soluble CXCL16 in human coronary heart disease (CHD) is still controversial. ObjectionTo investigate the changes of serum CXCL16 in Stable angina pectoris patients before and a period of time after they were implanted with rapamycin eluting stent.Methods40 patients diagnosed with stable angina pectoris (SAP) at our cardiovascular department, were enrolled in this study.10 patients with non-coronary heart disease (CHD) served as controls. All cases received coronary arteriography. Serum CXCL16, Hs-CRP was obtained by commercial ELISA and Gensini score was calculated by Judkins. Other parameters including HDL-C, LDL-C, TG, TC,WBC,Cr was detected by general biomedical method. The family history of DM, blood hyperpressure and CHD was collected.Results1. In the control group, serum CXCL16 level in different time (preoperative and postoperative 0.5 h,2h,24h respectively(1833.6±19.78)ng/ml, (1800.6±32.74) ng/ml, (1912.4±40.45)ng/ml, (1805.5±32.50)ng/ml, each group was not statistically significant (P>0.05). In the SAP group with stent, compared with preoperative (2118.1±51.78)ng/ml, serum CXCL16 level in postoperative 0.5 h reached peak (2827.5±32.74)ng/ml (P<0.05), postoperative 2h dropped slightly (2805.1±40.45) ng/ml (P<0.05), fall into (2124.0±32.49) ng/ml level after PCI 24h (P>0.05). Compared with the control group, serum CXCL16 level of SAP with stent group in different time (preoperative and postoperative 0.5 h,2h,24h) are higher than the control group (P<0.05).2. In the control group, serum Hs-CRP levels in different time (preoperative and postoperative 0.5 h,2h, respectively (903.57±7.63)ng/ml,(897.60±15.81)ng/ml, (905.53±10.52)ng/ml,(911.63±9.92)ng/ml, each group was not statistically significant (P>0.05). In the SAP group with stent,compared with preoperative (917.54±15.54) ng/ml, serum CXCL16 level in postoperative 0.5h reached peak (2455.34±80.75) ng/ml(P<0.05), postoperative 2h dropped to (2450.50±27.22) ng/ml (P<0.05),fall into (2146.56±43.16) ng/ml level after PCI 24h,but still higher than that before implant level (P<0.05). Compared with the control group, serum Hs-CRP levels have no statistically significant in SAP group with stent before PCI (P >0.05),but higher than the control group postoperative 0.5 h,2h,24h (P<0.05).3. No significant association was found between serum CXCL16 in patients between the before PCI group and Gensini score (r=0.003, P=0.452)ConclusionsSerum CXCL16 showed higher levels in SAP patients after PCI,CXCL16 is associated with atherosclerosis stbale,... |
PDF Full Text Request